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Abstract
This paper studies the consequences of parallel import (PI) on process innovation of …rms heterogeneous in their production technology. In an international
setting where foreign markets di¤er with respect to their intellectual property
rights regime, a move by a technologically inferior …rm to exploit a new unregulated market can result in imitation and PI. The impact of PI on innovation
is determined by the degree of heterogeneity between …rms and trade costs.
Increasing trade costs shifts from the market share losses brought by PI from
the more to the less productive …rm. This induces the former to invest more in
R&D. At this point, sales in the foreign market become a determinant of the
R&D decision by the technologically inferior …rm. For low levels of …rm heterogeneity, PI increases output by this …rm targeted for the unregulated market,
hence increases its Innovation e¤orts. A tari¤ policy accompanied by opening
borders to PI only increases welfare when the technological gap between the
two …rms are su¢ ciently large.
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1

Introduction

The debate about parallel imports (PI) and the views on their impact in the global
economy have become increasingly controversial in recent years. Generally de…ned,
PI are unauthorized re-imports of genuinely produced commodities back to the country of the original producer. The issue has by and large been associated with price
discrimination, vertical price control, and national price regulations.1 When goods
sold by a patent holder to a foreign market at a lower price are imported back to the
original country, the producer faces competition with its own goods o¤ered at a lower
price. This also reveals an important connection between PI and the protection of
intellectual property rights (IPR).
In this paper, we aim to explore the e¤ect of PI on innovation in emerging
economies with TRIPS obligations to upgrade their IPR regime. Entering a market
where IPR are not respected enables foreign manufacturers to imitate and send a
part of their output back to the original market to exploit an arbitrage opportunity.
While consumers may gain from lower prices, this may provoke consequences on the
innovative behavior of di¤erent type of …rms, and hence the fate of the industry.
The Patent Act 2005 of India created major concerns in the pharmaceutical
industry, one of its greatest points of strength since decades. While generic drugs
have been freely and skillfully produced in India, the Patent Act prohibited the
production of generics whose patents have not expired.2 On the optimistic side, this
can be a …rst step towards taking a leading role in innovating original medicine. It
could however be accompanied by a sudden surge in prices of pharmaceuticals in
India and hence limited access to medicine by a great portion of the population.
Interestingly, according to the TRIPS agreement each WTO member has the
sovereignty to choose its own policy on PI. This could be seen as an opportunity
to mitigate the negative e¤ects of IPR protection on consumers, made possible by
allowing imports of generic products from a market still unregulated in terms of
IPR. There have been rather skeptic views with regards to PI in the international
trade literature, precisely for cases such as the rapidly evolving Indian pharmaceutical industry. In particular, an important question that has been raised is: “does
allowing PI reduce R&D by Indian pharmaceuticals, and thereby impede the road
taken towards the development of its own innovative rather than an imitative phar1

See Maskus and Chen (1994), Richardson (2002), Valletti (2006), Ganslandt and Maskus (2007)

and Grossman and Lai (2008).
2
All patents registered before 1995 cannot be protected in India despite being protected elsewhere. Therefore, they could still be produced as generics in India.
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maceutical industry?”
To account for the particular characteristics of the Indian pharmaceutical industry, we separate the market into two groups: (i) large scale companies such as
Ranbaxy, Dr. Ready, or Cipla, which pursue a catch up strategy by engaging in
innovation in order to challenge leading …rms in developed countries; (ii) medium
…rms such as Lincoln, Simrone, and Aurochem, commonly referred to as specialized
operators.3 Both types of …rms possess patents, but di¤er with respect to their
R&D capabilities. The more e¢ cient large scale companies are competent to enter
less risky regulated markets such as the US or the EU. On the other hand, medium
…rms are technologically inferior and seek new unexploited markets to compensate
for their competitive disadvantage. Such destination markets are often unregulated,
where local manufacturers can reproduce and sell imitation products back in the
original market.
A good example of such unregulated market is Tanzania, which under TRIPS is
not required to enforce IPR in pharmaceuticals until 2016.4 In addition, it is the
only new frontier in Africa since 2002 with capabilities to replicate active principle
ingredients (API) besides Egypt, which has been active since 1992. There are 32
other African countries, which are only capable of producing formulations. As formulation manufacturing already exists in Tanzania, workers in Indian subsidiaries
may defect and disseminate information to local manufacturers. They can then use
their absorptive capacity to produce the similar …nal good that contains the patented
API and sent it back to India.
The literature on the impact of PI on innovation is rare and mostly focuses on
the R&D decision of a monopolist when its distributor engages in PI. Innovation has
been modelled in several forms with mixed results. Valletti and Szymanski (2006)
look at product innovation, where more R&D translates into higher quality products.
They …nd the impact of PI to be negative on R&D incentives, even if the monopolist
may introduce a new lower quality brand to compete with the generic drug. Li and
Robles (2007) instead …nd the conditions under which PI increases incentives to
innovate a new horizontally di¤erentiated version of the product. Li and Maskus
(2006) consider cost reducing process innovation and show that PI always inhibits
R&D. Li (2006) adds to this by examining competition between two symmetric …rms
in the home country and …nds ambiguous results on innovation that depending on
3
4

See Chaudhuri (2005a, 2005b).
India holds the highest number of registered patents in Tanzania and accounts for 1315 drug

products registered there in 2007, which is more than one third of the total. Kenya is ranked second
with 307 registered drugs. See Chaudhuri (2008) for more details.
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transportation cost. The results in the above work are derived under the implicit
assumption that IPR are perfectly enforced across the globe.
We build a theoretical framework to study the consequences of PI on innovation
in the context of an emerging market, such as the Indian pharmaceutical industry. In particular, we analyze the strategic innovative activities of technologically
asymmetric …rms competing in the home country to understand the impact of PI
from an unregulated market where IPR are not protected. We choose to focus on
process innovation as we believe it is more appropriate for describing an emerging
economy. Indeed, a detailed analysis of the Indian pharmaceutical industry before
and after the Patent Act shows a remarkable increase in process innovation whereas
no new product has been introduced in this period (Arora, Branstetter and Chatterjee, 2008). Our main contribution lies in introducing features to study PI in
such developing markets, namely asymmetric technologies and imperfect IPR enforcement, which together shed light on a number of noteworthy implications absent
from previous literature.
More precisely, our model adopts the concept of Leahy and Neary (1997) and
Zigic (1998) to build a two stage game where …rms invest in cost-reducing innovation
and compete in quantity. We build a three country model with two heterogeneous
…rms located in the home market. The more technologically advanced …rm serves
a regulated foreign market, whereas the less e¢ cient …rm enters an unregulated
one. By comparing the optimal R&D investment with and without PI from the
unregulated market, we demonstrate that R&D investment by each type of …rm
crucially depends on the extent of …rm heterogeneity and trade costs.
We …nd that the damages from PI are absorbed by the large …rm under free
trade, reducing R&D e¤ort by both …rms. Trade costs tend to transfer the burden
brought about by PI in terms of lower market share to the medium …rm. This gives
signi…cance to competition in the home market, where PI creates a ’domino’e¤ect
inducing the technologically superior …rm to strategically increase its R&D. On the
other hand, it is the foreign market that plays the principal role in the R&D decision
of the medium …rm. PI encourages R&D investment by the technologically inferior
…rm when it increases its foreign sales, which is more likely to occur for low degrees
of …rm heterogeneity. Finally, we show that tari¤s can only make the international
exhaustion system welfare optimal if the technology gap between …rms is large. This
could explain why allowing PI may be justi…ed in India, but not in Europe or the
US.
The paper is structured as follows. Section 2 describes the basics of the model.
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Section 3 solves the game with and without a ban on PI. Section 4 compares the two
scenarios to analyze the incentives to innovate by each …rm and derives implications
for welfare. Section 5 concludes.

2

The Basic Framework

Consider a home country H, where two heterogeneous …rms, L and M , compete.
In our example of the Indian pharmaceutical industry, L represents a large-scale
company while M represents a medium …rm, which obtains its patent through the
so called "me-too" drugs, i.e. drugs that imitate existing products and consist
of only minor modi…cations.5 While both …rms can invest in cost-reducing R&D
activity, they di¤er in their ability to perform R&D. We assume that L enjoys a
superior production technology due to prior experience in the …eld. We abstract
from product di¤erentiation and assume full homogeneity between the two goods in
the eyes of consumers.6
There are two segmented foreign markets, the North and the South, labeled N
and S respectively. IPR are protected in N and H, while S remains an unregulated
market. We assume that in addition to the home market, …rm L serves the North,
where it does not face the threat of imitation.7 On the contrary, …rm M enters the
unexploited Southern market, where IPR are not recognized.8 Local manufacturers
in S could hence freely reproduce the drug and sell it not only in S, but also export to
H at cost t giving rise to PI. We consider only one …rm in S and assume that it does
not possess the technology to engage in cost-reducing R&D.9 The home government
has the possibility to ban PI or allow it if it considers that social welfare is damaged
by such a practice.
5

This is for instance incremental innovation to the product, which has already been invented by

the big …rm. Thus, no initial large …xed cost are involved.
6
This is done so without the loss of generality as the results remain the same even when products
are not fully homogeneous.
7
Adding a Northern market into the model also serves to avoid creating an unbalanced market
size bias in favor of the M …rm.
8
We can think of FDI as the mode of serving the foreign market. Adding a symmetric …xed cost
of FDI will not alter the framework as both L and M have an addtional foreign market both under
PI and no PI.
9

This re‡ects the fact that foreign goods in less developed countries comprise a large fraction of

sales compared to local production ( for evidence in Tanzania, see Chaudhuri, 2008). In our model,
this comes due to the cost advantage of the medium …rm with respect to the less e¢ cient local …rm.
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We adopt the familiar linear demand function for each country:
pi = a

Qi

i = H; N; S:

(1)

For the sake of simplicity, markets are equal in size, captured by a. Depending on
whether PI is allowed or not, either two or three …rms operate in H. The L …rm
enjoys a monopoly position in N due to the enforcement of IPR, while the M …rm
competes with a local …rm in S. More precisely,

QH

(

QN

= q LN ;

P
QN
H = q LH + q M H

QPHI = qLH + qMH + qSH

;
(2)

QS = qMS + qSS ;
where the …rst subscript of q denotes the type of …rm, and the second the market it
serves. Superscripts N P and P I specify the scenario in which parallel imports are
banned and allowed respectively.
The cost function for each …rm is
cL = c
cM

= c

cS

= c;

1p
xL ;
2
p
xM ;
2

(3)

where investment in cost reducing innovation is indicated by xL and xM for the
L and M …rms. Parameter c is the pre-innovation production cost equal across
…rms. We assume that the lack of IPR protection in S allows the Southern …rm to
imitate the product, but not the production process. Parameter

2 [0; 1] captures

the technological di¤erence between the large-scale and the medium …rm.10 Finally,
a > c, xL

4c2 and xM

c

4

2

hold to assure non-negative marginal costs after

innovation.
The pro…t function for the L and M …rms are
L

M

= (pH

= (pH

cL )qLH + (pN

cL )qLN

xL ;

(4)

cM )qMH + (pS

cM )qMS

xM :

(5)

The pro…t of the Southern …rm is:
(
S

PI
S

10

= (pS

Alternatively, one can think of (1
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S

= (pS

cS )qSS

cS )qSS + (pH

cS

)qSH

:

(6)

) as the technology gap between the two …rms.
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3

Solving the Game

The two …rms in H play a two-stage game: in the …rst stage they invest in process
R&D and in the second stage they compete in quantity à la Cournot. We solve the
game …rst in the case where PI is forbidden and then in the case where it is allowed.

3.1

No Parallel Import

We start by considering the case in which PI is banned. Using backward induction,
second stage optimal quantities as a function of R&D investment can be computed
by taking the …rst order conditions of (4) and (5) using (1), (2) and (3):

qLH (xL ; xM ) =
qMH (xL ; xM ) =
qLN (xL ; xM ) =
qMS (xL ; xM ) =
qSS (xL ; xM ) =

a

c
3

a

c
3

+
+

p
2 xL
p

2

p
6

xM
6

p

xM

p

xL

;
;

xL
2
4
p
xM
a c
+
3
p3
xM
a c
3
6
a

c

+

(7)

By substituting the above expressions into the original home pro…t functions, we
solve for the optimal R&D investments by maximizing with respect to xL and xM
to get11
6(51
xL =
1071
xM

14 2 )
242 2

2

;

(8)

:

(9)

2

221
=
1071 242

2

Innovation by the L …rm is decreasing, while that of M is increasing in
with a lower technological gap. Substituting

, i.e.

= 1 in (8) and (9) reveals that the

technologically superior …rm always invests more in R&D, i.e. xL > xM :12
11

For the sake sake of exposition, we can eliminate (a

c) from the …nal form equations as it

appears in a multiplicative form in front of all optimal values of R&D investment, quantity, and
pro…t.
12
Recall that the L …rm enjoys a monopoly position in its foreign market N , whereas the M …rm
competes in a duopoly in S,
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Substituting (8) and (9) in (7), optimal quantities can be calculated and are
qLH

=

qMH

=

q SS

=

3(306 97 2 )
2(306 71 2 )
;
;
q
=
LN
2(1071 242 2 )
1071 242 2
2
306 + 7 2
7(51
)
;
q
=
;
MS
2
1071 242
1071 242 2
714 235 2
:
2(1071 242 2 )

The derivatives of the optimal quantities w.r.t.
@qLi =@

< 0, @qSS =@

< 0 and @qMi =@

(10)

convey the expected results that

> 0, for i = L; M . Note that a higher

not only reduces the productivity gap between L and M , but also gives M a higher
technological edge over the Southern …rm in S.
Plugging the optimal R&D investments and quantities back into (4) and (5)
yields optimal pro…ts:
L
M

= (qLH )2 + (qLN )2

xL ;

(11)

= (qMH )2 + (qMS )2

xM :

(12)

As with the innovation e¤orts, pro…t of the L …rm is decreasing, while that of
the M …rm is increasing in : @

L =@

< 0 and @

M =@

> 0:13

Finally, consumer surplus in the home country without PI amounts to
CSH

(qLH + qMH )2
;
=
2

and is increasing in :The direct e¤ect of
qLH , i.e. @qMH =@

3.2

> @qLH =@

on qMH outweighs its indirect e¤ect on

; as it can be easily ascertained.

Parallel Import

We now look at the case in which PI is allowed into the home country, where
t(a

(13)

=

c) is the trade cost normalized by the size of the market. As in the previous

scenario, second stage optimal quantities can be calculated and are:

qLH (xL ; xM ) =
qMH (xL ; xM ) =
qSH (xL ; xM ) =

a
a
a

p
p
3 xL
xM
c+
+
;
4
p 8 p
3 xM
xL
c+
+
;
4
p 8 p
xM + xL
c 3
;
4
8

(14)

where qLN (xL ; xM ), qMS (xL ; xM ), and qSS (xL ; xM ) take the same form as in (7).
13

All explicit expressions for both regimes are presented in Appendix I.
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Next, we derive the optimal R&D investments, which are:
xL =

2(1008

2

[298 + 129 ] + 432 )
3(2448 623 2 )

2

;

(15)

2 (235 + 108 ) 2
;
(16)
2448 623 2
Innovation by both …rms is always increasing in trade costs . Similar to the no
xM =

PI case, innovation by the L …rm is decreasing, that of M is increasing in

, and

xL > xM is always true.
Optimal quantities are in turn:
qLH

=

qMH

=

q SS

=

2
8352
[2167 + 129 ] + 432
[289 + 215 ] + 720
;
q
;
=
LN
2
2448 623
2448 623 2
2
3(272
[17 24 ])
8(198 + 2 [17 24 ] + 216 )
;
q
=
;
(17)
MS
2
3(2448 623 )
2448 623 2
2
2
2(408
[143 + 18 ])
1584
[569 1353 ] 1656
;
q
=
:
SH
2
2448 623
3(2448 623 2 )

864

2

Comparative statics with respect to

replicate the mechanism at work under no PI.

Additionally, @qSH =@ < 0 as entering the home market is easier when the M …rm
is weak. Clearly, trade costs

expand output by the home …rms and reduce that by

the foreign …rm: @qSH =@ < 0, @qHH =@ > 0, @qMH =@ > 0.
Notice that there is a prohibitive level of trade costs that blocks PI by making
qSH = 0, which is
^=

(1584 569 2 )
:
3(1872 451 2 )

This threshold level of trade costs starts at ^j
^j

=1

=0

(18)

' 0:28 and monotonically falls to

' 0:24. Clearly, we are only interested in parameter values of

< ^, where

PI is a feasible option,

Optimal pro…ts for L and M in the presence of PI are:
L

= (qLH )2 + (qLN )2

xL ;

(19)

M

= (qMH )2 + (qMS )2

xM :

(20)

The comparative statics of pro…ts work in the same direction as in the case with
no PI, with the addition that pro…ts of both …rms are increasing in trade costs .14
Finally, consumer surplus in the home country is:
CSH =
14

(qLH + qMH + qSH )2
;
2

(21)

In a di¤erent context under demand uncertainty, Ra¤ and Schmitt (2007) show how PI may

incrase the pro…t of manufacturers.
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which is increasing in
e¤ect of

and decreasing in . The former is because the positive direct

on the output of M dominates the negative indirect e¤ect on the quantity

produced by the other …rms: @qMH =@
applies to the direct e¤ect of

> @(qLH + qSH )=@

. A similar argument

on the imports of the Southern …rm: @qSH =@

>

@(qLH + qMH )=@ .

4

Analysis and Policy Implication

4.1

The Impact on Innovation

Taking into account the role of both technological heterogeneity between …rms and
trade costs, we compare the innovation e¤ort carried out by …rms across the two
regimes. The critical levels of

above which PI increases cost-reducing R&D by L

and M can be found using (8), (9), (15) and (16), and are respectively:

L

=

44064
3(1071
M

where

L

<

M

< ^ for

=

31311 2 + 6382
242 2 )(144 43

12546 7981
72(1071 242

4
2

)

;

(22)

2
2

)

;

(23)

2 [0; 1]. Hence,

Lemma 1 Allowing PI is more likely to stimulate innovation by the more technologically advanced …rm as
0 for

>

M,

where

M

>

xL = xL

xL > 0 for

>

L,

xL = xM

xM >

L.

Proof Directly follows by inspecting (22) and (23).
Lemma 1 is illustrated with the aid of Figure 1, where the above threshold values
determine the partition of the parameter space. The …gure can be divided into three
regions: A, B, and C.
Region A depicts a situation of free trade or low values of

. PI decreases

R&D by both …rms due to added competition coming from imports of the Southern
…rm. Introducing PI reduces the market share of L and M in the home market
( qLH = qLH
.15

of

qLH < 0 and

qLM = qMH

qMH < 0), more so the lower the value

This is the case because imports from the South are at their highest level

when the M …rm is relatively ine¢ cient.
15

The di¤erence between the variables of interest across the two regimes can be found in Appendix

II.
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Figure 1: Innovation
0:2

xL > 0
xM > 0
C

xL > 0
xM < 0

M

B

L

xL < 0
xM < 0

A

0

1

Imports tend to absorb more market share from the L …rm as long as
<~
with ~ <

L

in

88128
6(1071

175536 2 + 84593 4
() j qLH j > j qMH j ,
242 2 )(144 151 2 )

(24)

2 [0; 1].16 Increasing trade costs shifts the burden of PI from the

L to the M …rm and this is con…rmed by:

@(j qLH j j qMH j)
=
@

(144 151 2 )
< 0:
2448 623 2

(25)

We can therefore state:
Proposition 1 While for low

the reduction in market share brought by PI a¤ects

more the L …rm, increasing

transfers the burden to the M …rm. Given

Lemma 1, when trade costs are su¢ ciently large so that

>

L,

introducing

PI increases R&D investment by the L …rm.
Proof Directly follows from (24) and (25).
16

The threshold value ~ starts at

Published by Berkeley Electronic Press Services, 2010
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Proposition 1 explains how trade costs a¤ect the market size perceived by each
…rm, which in turn determines the incentives to engage in process innovation. When
trade costs protect L to give a su¢ ciently large edge over M , the former invests more
than under the no PI case. This entails a shift from region A to region B in Figure
1, and occurs when trade costs reach

=

L.

While allowing PI results in more R&D investment by L in region B, it reduces
that by M . Here, the foreign entrant steals more market share from the ’vulnerable’
M creating a "domino e¤ect" by making L more aggressive and stimulating its
innovation e¤ort. In region B, the Southern market starts to play a crucial role in
the R&D decision of M . Interestingly, solving

qMS = qMS

qMS for

PI induces M to increase its output destined for the South when

unveils that

>

M.

This is

more likely to occur when the technology gap between L and M is not signi…cant,
since @

M =@

< 0.

Using this result along with Lemma 1 con…rms that PI encourages also M to
devote more resources to R&D exactly when

qMS > 0. It follows that:

Proposition 2 Allowing PI from the South to the home market increases the output of the M …rm for the Southern market along with its R&D e¤orts when
>

M.

This is more likely for relatively high values of

Proof Directly follows from (23), and

.

qMS evaluated in Appendix II.

Proposition 2 suggests that PI may instigate M to increase its production for
the South and this is viable when it enjoys a large cost advantage with respect to
the Southern …rm. If so, we move to region C, where a combination of su¢ ciently
high values of

and

induces more process R&D by both …rms under PI. In

line with recent PI literature, our results reinforce the claim that PI may actually
enhance incentives to innovate by home …rms. It remains to evaluate whether PI
also improves aggregate welfare in the home country.

4.2

The Impact on Welfare

Let us …rst consider the case where trade costs do not generate revenues to the home
government. It follows that social welfare in H amounts to the sum of consumer
and producer surplus: WH = CSH +

H,

where

H

First of all, in the admissible range of trade costs
that
CSH = CSH

http://services.bepress.com/feem/paper429
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=

L

+

M.

2 [0; ^] ; we can demonstrate

CSH > 0;

(26)

12

Mantovani and Naghavi: Parallel Imports and Innovation in an Emerging Economy

as the entry of a third …rm into the home market always makes consumers better
o¤.17 Together with the results from the previous section on R&D, PI may eliminate
the conventional trade-o¤ between consumers’ well-being and …rms’ incentive to
innovate (area C in Figure 1). Nevertheless, looking at the supply side yields that
PI harms both …rms L and M , thus lowering home industry pro…t:
H

=(

L

+

M)

(

L

+

M)

< 0:

(27)

PI hence bene…ts consumers, but always at the expense of local …rms, regardless
of their resulting innovative activities. Weighing the magnitude of consumer gains
against producer losses reveals that:
Lemma 2 Introducing PI always reduces aggregate welfare in the home country as
WH =

CSH +

H

< 0:

Proof see Appendix III.
One solution to this dilemma could be the imposition of tari¤s on those imports
whose legitimacy is the object of our discussion.18 To investigate this possibility, we
simply consider trade costs to be tari¤s levied on PI. In this setting, social welfare
in H is augmented by tari¤ revenues
T =

q SH

(28)

and is de…ned by WHT = WH + T . A high tari¤ rate increases per unit revenue, but
reduces the total quantity of imports (@qSH =@ < 0). Additionally, @qSH =@
implies that total revenue is higher the lower the value of

<0

(@T =@ < 0).

Given Lemma 2, for PI to increase home welfare it must be true that
WHT = T +

WH > 0:

On the one hand, only a high tari¤ can su¢ ciently reduce the loss
make this feasible. On the other hand, T is hump-shaped in . As @T =@

(29)
WH to
< 0; a

relatively large degree of …rm heterogeneity is a pre-requisite for tari¤s to overturn
the detrimental result on welfare. We can deduce that
Proposition 3 A tari¤ on PI can make the international exhaustion system welfare
improving only if the technology gap between home …rms is su¢ ciently large.
17
18

All explicit formulation for the welfare comparison can be found in Appendix III.
Hur and Riyanto (2006) also use trade costs to show how PI can be bene…cial for the host country

in the presence of a tari¤ policy. Their analysis however abstracts from the role of innovation.
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Proof see Appendix III.
The intuition behind Proposition 3 is that social welfare is higher in H under PI
when it is possible to simultaneously mitigate the damage to home …rms and collect
a relatively high tari¤ revenue. The enforcement of tari¤s by the home government
is essential to reduce the pro…t loss (@ j

H j =@

< 0). However, as noted above, an

additional earning is necessary to make PI welfare improving. The tari¤ revenues
WHT > 0 for lor low values of

can only reach the critical level to satisfy

. The

cone-shaped area in Figure 2 represents the parametric region in which social welfare
is higher under PI when tari¤ revenues are taken into account.19

Figure 2: Welfare
0:3

WHT > 0

^

WHT < 0

0

5

1

Conclusion

In this paper we have examined the consequences of an international exhaustion
system in an emerging economy. In so doing, we have based our model on the Indian
19

Recall that above ^ the foreign …rm does not export to the H market.
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pharmaceutical industry, which after the Patent Act 2005 has experienced a surge
in PI arriving from markets not yet obliged by TRIPS to enforce IPR protection. A
good example is Tanzania, inferior both in terms of technology and IPR enforcement.
Such unexploited markets can serve as interesting destinations for less e¢ cient …rms
in the industry. In the Indian pharmaceutical sector …rms can be broadly categorized
into two types: (i) a larger company evolving with the aim of taking a lead role on
innovation and reach the global market; (ii) a medium …rms not as well endowed
with technology specializing in producing generics or incremental drugs.
We …nd that competition in the home market plays a major role in the R&D
decision of the large …rm. Trade costs transfer the loss brought about by PI from the
large to the medium …rm. This results in a less aggressive medium …rm, which then
increases the incentives of the dominant competing …rm to innovate. For the medium
…rm, it is sales in the foreign market that plays the decisive role in its decision to
invest in R&D. When a policy favoring PI paradoxically increases its grasp over the
Southern market, the medium …rm also increases its R&D e¤orts. This is more likely
for low degrees of …rm heterogeneity, which also implicitly implies a large enough
cost advantage over the Southern …rm.
As for welfare, although PI always bene…ts consumers through lower prices and
can increase innovation by both …rms, this comes at the expense of pro…ts in a catch
up phase where …rms seek competitiveness in the global market. Although trade
costs create a form of protection against PI, they never fully compensate …rms for
the losses brought about by such policy. Only when trade costs generate government
revenue, i.e. tari¤s, PI may also be welfare-enhancing for the home country. This
is only a possibility in the presence of large technological asymmetry between …rms,
which in turn assures su¢ cient revenues to overturn the welfare results.
We can conclude from our …ndings that in an emerging industry where the technology gap between …rms is large, an international exhaustion system accompanied
by tari¤s can increase innovation and welfare in the home country. These are the
actual conditions that apply to the pharmaceutical industry in India, but not in fully
developed economies such as the US or EU, justifying assorted policies observed with
regards to PI in di¤erent parts of the world.
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Appendix I
In Appendix I we report the …nal form values of equilibrium pro…ts, consumer
surplus and total welfare, using (10), (8) and (9) for the PI and (17), (15) and (16)
for the no PI case.
No Parallel Import

L

=

4
1023876
(1071 242

137113

M

=

+1966356

;

(A1)

4

49555 2 +221085
;
(1071 242 2 )2

98

CSH =
WH =

2

2 2
)

2(277
8(242

2
2

(A2)

1530)2
;
1071)2

(A3)

8042292 3291812 2 +351739
8(1071 242 2 )

4

:

(A4)

Parallel Import

L

=

26790912 4896

2

[3034+1641 +645

2 ]+ 4 [2093927+1267554

12(2448 623

+471495

2 ]+1057536

(12+5 )

2 2
)

(A5)
M

=

8501760 108

2

[21355+8408 +10032 2 ]+145 4 [24
9(2448 623 2 )2

CSH =
WH =

60244992 48

2

8[1440 325 2 3 (144 43
9(2448 623 2 )

17]2 +497664 (11+6 )

2

(A6)

2

)]

:

(A7)

[581533+47646 +120654 2 ]+ 4 [3276467+215394 +760359
12(2448 623 2 )2

2 ]+62208

(108+181 )

:

(A8)

Appendix II
In this appendix we present the di¤erences in both quantity and investment levels
that appear in Section 4.1. The sign of the following expressions has been evaluated
in the relevant interval region
q LH =
q MH =
20

396576 18

2 [0; 1] [
2

2 [0; ~]:20

(13726 44945 )+ 4 (41417 104060 ) 1542240
2(1071 242 2 )(2448 623 2 )

550800 3422 (827 1824 )+ 4 (19829 46464 ) 1850688
3(1071 242 2 )(2448 623 2 )

< 0;

< 0;

(A9)
(A10)

Addional calculations and precise graphical representations for this and the following appendix

are available upon request.
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2

q MS =
4
9

xL =

n

=

3

2

2

[2203200 9

[44064 9

xM

[12546 2 (7981 17424 ) 77112 ]
>
(1071 242 2 )(2448 623 2 )

2

>

M,

(A11)

(128611+26967 )+2 4 (15609 +75307)+462672 ]
(1071 242 2 )2

(A12)

(3479 26967 )+2 4 (3191 15609 ) 462672 ]
(2448 623 2 )2

2

[1044378

> 0 for

0 for

>

o

> 0 for

>

L;

(251423+52272 )+231336 ][12546 2 (7981 17424 ) 77112 ]
(1071 242 2 )2 (2448 623 2 )2

M:

(A13)

Appendix III
In this appendix we evaluate the sign of the inequalities that appear in Section
4.2. First of all:

CS H

=

1
72

n

[1101600 18
2

[23574240 18

[22552103255040

H=

198288

2

(37699 107868 )+ 4 (111487 249744 ) 3701376 ]
(1071 242 2 )2

(581461 107868 )+ 4 (1146913 249744 ) 3701376 ]
(2448 623 2 )2

2

(116908819 317210334 152565966 2 )]+
36(1071 242 2 )2 (2448 623 2 )2

4

o

(A14)
> 0;

71355126528 (964+447 )

< 0;

(A15)
where:

+7

4

=[8944586709615 36 2 (43070165909 3350119771944 1715020497036 2 )+
(14660626163 27854561064 14628994380 2 ) 729 (29777635094+14803179645 )]:

Moreover,
@j
@

Hj

=

9994752 144

2

(32101+31962 )+7 4 (79271+83265 )+9268992
6(2448 623 2 )2

< 0:

(A16)

Taking into account the di¤erences on social welfare, both with and without
additional tari¤ revenues, we obtain:
W H=

6378274575360 396576

2

(15832613 30793098 6293653 2 )+ 4
24(1071 242 2 )2 (2448 623 2 )2

142710253056 (108+181 )

< 0;

(A17)
where
+

4

=[2298423778038 108 2 (3567658219 4547941332 13579811366 2 )+
(25794292217 25228668432 89059328952 2 ) 1458 (2504840178+6218960351 )]
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and
2

6378274575360 396576

W TH =

4

(15832613 126405314 +23842001 2 )+
24(1071 242 2 )2 (2448 623 2 )2

47570084352 (1072+2109 )

;

(A18)
where
+

4

=[2298423778038 36 2 (10702974657 85448407748 +144996813654 2 )+
(25794292217 191310081776 +305858337576 2 ) 486 (38251547402 68627567319 )]:

Finally, we prove Proposition 3 by solving for the value of

that determines the

condition under which PI can be welfare enhancing. From (A18):
WHT

= 0 =)
=

23807250432 2

(A20)
2

2

4

(9011812464 2303178705 +197634382 )
6(14577408 7150752 2 +870439 4 )(1071 242

p
2

2 (2448 623
)

2

)

;

where
=743646624768 2571277828320

2

+

4

(2017891648980 455187836484

2

+27726926171

4

):

More speci…cally,
WHT
where

and

represented in

+

0 when t 2 [

;

+] ;

are the two threshold values coming from (A20). They can be

2 [0; 1], giving rise to the cone represented in Figure 3.
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